Perrigo EBITDA Margin 2010-2024 | PRGO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Perrigo (PRGO) over the last 10 years. The current EBITDA margin for Perrigo as of September 30, 2024 is .
| Perrigo EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-09-30 | $4.39B | $0.32B | 7.22% |
| 2024-06-30 | $4.43B | $0.31B | 6.95% |
| 2024-03-31 | $4.56B | $0.40B | 8.85% |
| 2023-12-31 | $4.66B | $0.51B | 11.04% |
| 2023-09-30 | $4.65B | $0.57B | 12.31% |
| 2023-06-30 | $4.63B | $0.54B | 11.71% |
| 2023-03-31 | $4.56B | $0.46B | 10.18% |
| 2022-12-31 | $4.45B | $0.42B | 9.37% |
| 2022-09-30 | $4.40B | $0.41B | 9.22% |
| 2022-06-30 | $4.35B | $0.79B | 18.25% |
| 2022-03-31 | $4.20B | $0.67B | 15.89% |
| 2021-12-31 | $4.14B | $0.72B | 17.35% |
| 2021-09-30 | $4.09B | $0.74B | 18.01% |
| 2021-06-30 | $4.05B | $0.40B | 9.91% |
| 2021-03-31 | $4.02B | $0.61B | 15.19% |
| 2020-12-31 | $4.09B | $0.65B | 15.85% |
| 2020-09-30 | $3.39B | $0.58B | 16.99% |
| 2020-06-30 | $3.58B | $0.56B | 15.57% |
| 2020-03-31 | $3.78B | $0.55B | 14.53% |
| 2019-12-31 | $3.87B | $0.57B | 14.65% |
| 2019-09-30 | $4.71B | $0.71B | 15.01% |
| 2019-06-30 | $4.65B | $0.53B | 11.46% |
| 2019-03-31 | $4.69B | $0.59B | 12.48% |
| 2018-12-31 | $4.73B | $0.65B | 13.78% |
| 2018-09-30 | $4.82B | $0.71B | 14.80% |
| 2018-06-30 | $4.92B | $1.00B | 20.32% |
| 2018-03-31 | $4.97B | $1.05B | 21.19% |
| 2017-12-31 | $4.95B | $1.02B | 20.64% |
| 2017-09-30 | $4.99B | $0.39B | 7.79% |
| 2017-06-30 | $5.03B | $-1.24B | -24.70% |
| 2017-03-31 | $5.13B | $-1.21B | -23.54% |
| 2016-12-31 | $5.28B | $-1.57B | -29.69% |
| 2016-09-30 | $2.93B | $-1.77B | -60.30% |
| 2016-06-30 | $2.94B | $-0.13B | -4.46% |
| 2015-12-31 | $1.22B | $-0.04B | -3.62% |
| 2015-09-30 | $3.31B | $1.72B | 51.87% |
| 2014-12-31 | $3.03B | $1.68B | 55.38% |
| 2014-09-30 | $2.94B | $1.52B | 51.79% |
| 2013-12-31 | $2.83B | $1.51B | 53.43% |
| 2013-09-30 | $2.74B | $1.39B | 50.84% |
| 2012-12-31 | $2.43B | $1.33B | 54.50% |
| 2012-09-30 | $2.39B | $1.28B | 53.48% |
| 2011-12-31 | $2.26B | $1.17B | 51.97% |
| 2011-09-30 | $2.14B | $1.05B | 48.95% |
| 2010-12-31 | $1.90B | $1.00B | 52.56% |
| 2010-09-30 | $1.76B | $0.85B | 48.44% |
| 2009-12-31 | $1.62B | $0.81B | 50.06% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.716B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $203.157B | 25.91 |
| Stryker (SYK) | United States | $148.171B | 33.39 |
| Boston Scientific (BSX) | United States | $133.131B | 38.28 |
| EssilorLuxottica (ESLOY) | France | $113.461B | 0.00 |
| Medtronic (MDT) | Ireland | $109.010B | 16.19 |
| Haleon (HLN) | United Kingdom | $42.913B | 27.88 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.122B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.701B | 19.56 |
| ResMed (RMD) | United States | $34.955B | 28.72 |
| Terumo (TRUMY) | Japan | $29.203B | 41.24 |
| Koninklijke Philips (PHG) | Netherlands | $24.410B | 18.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.087B | 14.06 |
| Insulet (PODD) | United States | $18.377B | 73.18 |
| Baxter (BAX) | United States | $16.604B | 10.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.153B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.468B | 37.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.977B | 30.51 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.523B | 12.83 |
| TG Therapeutics (TGTX) | United States | $4.720B | 0.00 |
| Haemonetics (HAE) | United States | $4.260B | 20.79 |
| ICU Medical (ICUI) | United States | $4.155B | 39.56 |
| Prestige Consumer Healthcare (PBH) | United States | $4.074B | 20.26 |
| Envista Holdings (NVST) | United States | $3.487B | 25.97 |
| Neogen (NEOG) | United States | $3.270B | 37.72 |
| Agios Pharmaceuticals (AGIO) | United States | $3.103B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.789B | 17.89 |
| QuidelOrtho (QDEL) | United States | $2.595B | 16.70 |
| Warby Parker (WRBY) | United States | $2.344B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.332B | 56.69 |
| Green Thumb Industries (GTBIF) | United States | $1.964B | 34.37 |
| AtriCure (ATRC) | United States | $1.772B | 0.00 |
| InMode (INMD) | Israel | $1.487B | 8.94 |
| Curaleaf Holdings (CURLF) | Canada | $1.348B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.311B | 9.37 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.168B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.957B | 7.48 |
| CeriBell (CBLL) | United States | $0.916B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.888B | 29.68 |
| Capricor Therapeutics (CAPR) | United States | $0.839B | 0.00 |
| Evolus (EOLS) | United States | $0.785B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.608B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.596B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.596B | 26.47 |
| Surmodics (SRDX) | United States | $0.559B | 0.00 |
| Quanterix (QTRX) | United States | $0.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.404B | 0.00 |
| Valneva SE (VALN) | France | $0.370B | 0.00 |
| ZimVie (ZIMV) | United States | $0.363B | 30.63 |
| Omeros (OMER) | United States | $0.349B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.335B | 31.89 |
| Biote (BTMD) | United States | $0.330B | 7.25 |
| Sanara MedTech (SMTI) | United States | $0.323B | 0.00 |
| Cerus (CERS) | United States | $0.312B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.288B | 19.30 |
| Zynex (ZYXI) | United States | $0.249B | 52.13 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.229B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.219B | 15.15 |
| MacroGenics (MGNX) | United States | $0.218B | 0.00 |
| High Tide (HITI) | Canada | $0.215B | 89.00 |
| Sanuwave Health (SNWV) | United States | $0.195B | 2.74 |
| Jin Medical (ZJYL) | China | $0.188B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.162B | 0.00 |
| Brainsway (BWAY) | Israel | $0.161B | 96.70 |
| Organigram Holdings (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.98 |
| TriSalus Life Sciences (TLSI) | United States | $0.126B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 10.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 23.00 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.082B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.080B | 41.50 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.066B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| Exagen (XGN) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.052B | 0.00 |
| Apyx Medical (APYX) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.026B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.17 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |